Aimia Inc. (TSX:AIM)
2.750
+0.040 (1.48%)
Aug 27, 2026, 3:59 PM EST
Aimia Revenue
Aimia had revenue of 36.40M CAD in the quarter ending June 30, 2026, a decrease of -3.70%. This brings the company's revenue in the last twelve months to 314.00M, down -6.21% year-over-year. In the year 2025, Aimia had annual revenue of 503.40M with 0.52% growth.
Revenue (ttm)
314.00M
Revenue Growth
-6.21%
P/S Ratio
0.47
Revenue / Employee
211.95K
Employees
2,385
Market Cap
239.57M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 503.40M | 2.60M | 0.52% |
| Dec 31, 2024 | 500.80M | 209.60M | 71.98% |
| Dec 31, 2023 | 291.20M | 289.70M | 19,313.33% |
| Dec 31, 2022 | 1.50M | -11.10M | -88.10% |
| Dec 31, 2021 | 12.60M | -1.70M | -11.89% |
| Dec 31, 2020 | 14.30M | -113.00M | -88.77% |
| Dec 31, 2019 | 127.30M | -39.80M | -23.82% |
| Dec 31, 2018 | 167.10M | -65.00M | -28.01% |
| Dec 31, 2017 | 232.10M | -1.53B | -86.81% |
| Dec 31, 2016 | 1.76B | -701.30M | -28.50% |
| Dec 31, 2015 | 2.46B | -8.20M | -0.33% |
| Dec 31, 2014 | 2.47B | 795.30M | 47.52% |
| Dec 31, 2013 | 1.67B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Neo Performance Materials | 856.59M |
| 5N Plus | 634.95M |
| AirBoss of America | 596.63M |
| Tidewater Renewables | 370.90M |
| EcoSynthetix | 28.50M |
| California Nanotechnologies | 4.12M |
| Graphene Manufacturing Group | 396.88K |
| HydroGraph Clean Power | 126.75K |
Aimia News
- 16 days ago - Aimia Q2 Earnings Call Highlights - MarketBeat
- 16 days ago - Aimia Earnings Call Transcript: Q2 2026 - Transcripts
- 16 days ago - Aimia Earnings release: Q2 2026 - Filings
- 16 days ago - Aimia Registration statement: Q2 2026 - Filings
- 16 days ago - Aimia Registration statement: Q2 2026 - Filings
- 16 days ago - Aimia Slides: Q2 2026 - Filings
- 17 days ago - AIM ImmunoTech Releases Q2 2026 Financial Results - AlphaStreet
- 23 days ago - AIM Doses Last Patient Early In Phase 2 DURIPANC For Ampligen In Treating Pancreatic Cancer - Nasdaq